Owing to the dysregulation of protein kinase activity in many diseases including cancer, this
enzyme family has become one of the most important drug targets in the 21 st century. There …

The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer
therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology …

Rheumatoid arthritis (RA) is an incurable systemic autoimmune disease. Disease
progression leads to joint deformity and associated loss of function, which significantly …

Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that
currently combines the selectivity of monoclonal antibodies with the potency of a payload …

The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

Inflammatory bowel disease (IBD), as a representative inflammatory disease, currently has
multiple effective treatment options available and new therapeutic strategies are being …

Proteolysis targeting chimeric (PROTAC) technology is an effective endogenous protein
degradation tool developed in recent years that can ubiquitinate the target proteins through …

B lymphocytes have a central role in autoimmune diseases, which are often defined by
specific autoantibody patterns and feature a loss of B cell tolerance. A prototypic disease …

Vascular endothelial growth factor receptors (VEGFRs) are a family of receptor protein
tyrosine kinases that play an important role in the regulation of tumor-induced angiogenesis …

Targeted protein degradation (TPD) refers to the use of small molecules to induce ubiquitin-
dependent degradation of proteins. TPD is of interest in drug development, as it can address …